BMY Q1 2025 Earnings — Bristol-Myers Squibb Company Revenue & Financial Results | Market Cap Arena

BMYBristol-Myers Squibb Company

$124B

Q1 2025 Earnings

Healthcare Drug Manufacturers - General

Income Statement

Revenue

$11.2B-5.6% YoY

Gross Profit

$7.3B65.5% margin

Operating Income

$3.5B31.4% margin

Net Income

$2.5B21.9% margin

EPS (Diluted)

$1.20

QoQ Revenue Growth

-9.2%

Cash Flow

Operating Cash Flow

$2.0B

Free Cash Flow

$1.7B

Stock-Based Comp.

$144M

Balance Sheet

Total Assets

$92.4B

Total Liabilities

$75.0B

Stockholders' Equity

$17.4B

Cash & Equivalents

$10.9B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11.2B	$11.9B	-5.6%
Gross Profit	$7.3B	$6.6B	+11.4%
Operating Income	$3.5B	$1.5B	+129.4%
Net Income	$2.5B	-$11.9B	+120.6%

Revenue Segments

Eliquis

$3.6B32%

Opdivo

$2.3B20%

Revlimid

$936M8%

Orencia

$770M7%

Pomalyst/Imnovid

$658M6%

Yervoy

$624M6%

Reblozyl

$478M4%

Other Growth Brands

$403M4%

Breyanzi

$263M2%

Opdualag

$252M2%

Other Legacy Brands

$199M2%

Sprycel

$175M2%

Camzyos

$159M1%

Zeposia

$107M1%

Abraxane

$105M1%

Abecma

$103M1%

Sotyktu

$55M0%

Krazati

$48M0%

Cobenfy

$27M0%

Opdivo Ovantig

$9M0%

Geographic Segments

UNITED STATES

$7.9B70%

Rest Of World

$3.1B28%

Other Region

$218M2%